HNN3.0
Register
Register
Register

Project cooperationUpdated on 2 February 2026

Insulin and IGF Signalling Mechanisms in Metabolic, Cardiovascular and Cancer Diseases

group leader at IOCB Prague

Praha, Czech Republic

About

We investigate disease-relevant molecular mechanisms of insulin and insulin-like growth factor (IGF1/2) signalling, focusing on receptor specificity, pathway selectivity and dysregulation in metabolic, cardiovascular and cancer-related conditions.

Using synthetic insulin and IGF analogues, peptide mimetics and receptor-selective tools, we dissect metabolic versus mitogenic signalling and their contribution to disease phenotypes. Our work addresses fundamental mechanisms underlying insulin resistance, altered growth signalling and hormone-driven disease progression.

We seek to contribute as a scientific partner to Horizon Europe Health projects focused on disease mechanisms, biomarkers and targeted therapeutic strategies, including topics related to cardiovascular diseases, metabolic disorders and cancer.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

Type

  • Partner seeks Consortium/Coordinator

Organisation

IOCB Prague

R&D Institution

Prague, Czech Republic

Similar opportunities

  • Project cooperation

    Insulin and IGF Analogues for Targeted Modulation of Metabolic and Mitogenic Signalling

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Jiri Jiracek

    group leader at IOCB Prague

    Praha, Czech Republic

  • Project cooperation

    Connected medical devices and real-world data to support sex and gender-specific cardiovascular research

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Celia Bengougam

    Medical Affairs Team Leader at Withings

    Paris, France

  • Project cooperation

    Early detection of heart failure in metabolic and high-risk cardiovascular diseases

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Slavica Mitrovska

    Cardiologist at Polyclinic Biotek

    Skopje, North Macedonia